Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Closed vs Open Triple Therapy in COPD
NCT02731846Phase 3Withdrawn
- Sponsor
- GSK
- Start
- Jun 2016
- Primary completion
- Nov 2016
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of fluticasone in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by GSK. Primary endpoint: Change from baseline in trough forced expiratory volume in one second (FEV1) at Day 29. Planned start Jun 2016; status: withdrawn.
02
Drugs
fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT02731846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731846.